Supernus Pharmaceuticals | SUPN - Debt


Supernus Pharmaceuticals reported $31.77M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Abbott USD 12.94B 496M Sep/2025
ANI Pharmaceuticals USD 620.31M 1.25M Sep/2025
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.6M 2.03M Jun/2025
Eisai JPY 187.52B 31.58B Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 376.72M 203.77M Sep/2025
Perrigo USD 3.65B 454.7M Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025